ITEM 8.01 Other Events.

On April 25, 2022, Intra-Cellular Therapies, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") has approved new dosage strengths for CAPLYTA® (lumateperone) for specific patient populations.

The Company's press release announcing the FDA's approval is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 9.01 Financial Statements and Exhibits.




(d)   Exhibits

Exhibit
Number       Description

99.1           Press release dated April 25, 2022

104          Cover Page Interactive Data File (embedded within the Inline XBRL document)

The press release may contain hypertext links to information on our website. The information on our website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses